TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs it can position for partnerships.

A decision to possibly sell the business, which was poised to become the centerpiece of a restructuring plan, represents a shift in strategy by new company leaders.

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused ...

The action will remove from use the very few flu shots that contain the contested preservative, elevating unproven fears it ...

The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in ...

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of ...

George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

Experts on the panel shared many of the same views around SSRIs, arguing the risks of the drugs during pregnancy are greater than currently accepted.